<DOC>
	<DOCNO>NCT00606632</DOCNO>
	<brief_summary>This multicenter Phase III study demonstrate diagnostic utility 124I-cG250 PET/CT pre-surgical imaging patient operable renal mass .</brief_summary>
	<brief_title>Pre-surgical Detection Clear Cell Renal Cell Carcinoma ( ccRCC ) Using Radiolabeled G250-Antibody</brief_title>
	<detailed_description>A preoperative 124I-cG250 PET scan may distinguish clear cell non-clear cell renal carcinoma patient renal mass . Studies image characteristic 124I variety PET camera , quantification tumor uptake 124I-labeled antibody correlation biopsy measurement tumor normal tissue meet encouraging result . As clear cell renal cancer associate aggressive phenotype priori determination may help guide appropriate surgical/therapeutic management .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Subject 18 year age . Presence renal mass . Scheduled surgical resection renal mass ( partial total nephrectomy , open laparoscopic technique ) . Expected survival least 3 month . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 . The following laboratory result within follow limit within last 2 week prior study day 1 : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Serum bilirubin ≤ 2.0 mg/dL Aspartate aminotransaminase ( AST ) ≤ 2.5 x ULN Alanine aminotransferase ( ALT ) ≤ 2.5 x ULN Serum creatinine ≤ 2.0 mg/dL ( calculated creatinine clearance &gt; 45 ml/min ) Negative serum pregnancy test ; perform female patient childbearing potential within 24 hour prior receive investigational product . All female childbearing potential must indicate intent avoid pregnancy must use accept , effective method contraception duration study . Recovered toxicity prior therapy . Able willing give valid write informed consent . Metastasis primary tumor Renal Cell Carcinoma ( RCC ) . Prior history malignancy within last 5 year . Prior exposure murine proteins chimeric antibody . Intercurrent medical condition may limit amount antibody administer . Intercurrent medical condition render patient ineligible surgery . New York Heart Association Class III/IV cardiac disease . History autoimmune hepatitis . Chemotherapy , radiotherapy , immunotherapy within 4 week prior 124IcG250 infusion day 1 . Mental impairment may compromise ability give informed consent comply requirement study . Lack availability immunological clinical followup assessment . Participation clinical trial involve another investigational product within 4 week prior enrolment . Women pregnant breastfeeding . Allergy iodine , hyperthyroidism , Grave 's Disease . Known allergic reaction human serum albumin . Contraindication contrastenhanced CT PET/CT . Contraindication potassium iodide intake ( see package insert ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Renal Mass</keyword>
	<keyword>Clear Cell Renal Cell Carcinoma</keyword>
	<keyword>Cancer Kidney</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>cG250</keyword>
	<keyword>antibody , monoclonal</keyword>
	<keyword>Iodine 124</keyword>
	<keyword>Positron-Emission Tomography</keyword>
	<keyword>Kidney</keyword>
	<keyword>Renal Cancer</keyword>
	<keyword>Renal Neoplasms</keyword>
</DOC>